A new cancer drug may be able to inhibit both tumor growth and the spread of aggressive prostate cancer. This is shown in a ...

In the United States, prostate cancer is a leading cause of cancer-related disease and death in men. About half of prostate ...

An AI-powered biomarker based on histology alone predicted survival among men with metastatic hormone-sensitive prostate cancer and identified those who benefitted from escalation to triplet therapy.

Tiny silica nanoparticles engineered to seek out prostate cancer caused tumor cells to self-destruct and supercharged the ...

Prostate cancer is the second most common cancer for men in the United States (after skin cancer) and is the second leading cause of cancer deaths (after lung cancer). The American Cancer Society ...

There may be a "promising new strategy" in combating aggressive forms of prostate cancer, according to a new study. Researchers at Flinders University and the University of South Australia ...

PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November ...

A team tests the protective effect of a fermented black garlic extract against inflammation and the progression of prostate cancer in a study conducted on human prostate cancer cell models in the ...

A newly expanded prostate cancer drug could bring new hope to patients with a common form of the disease. Novartis, a Switzerland-based pharmaceutical company, announced on March 28 that the U.S. Food ...

Prostate cancer is the fifth leading cause of death from cancer (after lung, liver, colorectum and stomach) across the world and the third most common cause of death from male specific cancers in ...

When prostate cancer has spread beyond the prostate to nearby lymph nodes and other areas of the body and treatments can no longer slow or stop its growth, you are not alone. Many patients, despite ...